Program Overview
Performance Indicators
Key performance indicators for 2010-11
- Commercial availability of parasite treatments that address resistance and are cost competitive with existing treatments or guidelines on use of treatments to minimise development of resistance included with commercial products by 2015
- Participation in two international collaboration areas of priority to industry
- Report on the conclusions established from the musculoskeletal workshop, outlining research plans and objectives for the next 5 years that will stimulate project submissions from these researchers
- Produce a single report for the horse industry that summarises the significant findings from RIRDC funded studies noted above, allowing the findings to be adopted by greater than 50 per cent of the industry. Areas needing additional research will be identified
- Objective evidence of reduced embryonic loss linked to the use of the strategies/tests
- Objective evidence of the impact of management regimes for target diseases in foals
- Assist equine industry organisations to provide information to support the development or implementation of strategies to improve horse or human safety in their industry segment by 2011
- Contribute to the development of international cooperative research on detection of therapeutic and prohibited substances
- Support drug administration trials to produce a knowledge base for use by both regulators and industry participants
- Ensure industry engagement in the development of management strategies introduced by government agencies for reducing the environmental impact of horses is backed by sound research attracting at least two new investors in the Program
- Positive feedback from industry organisation members on communication.
